Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will attend the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.'s Annual Virtual Healthcare Conference on May 20, as per a press release.
This participation comes on the heels of significant momentum for Tonix, which recently received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. Fibromyalgia affects millions of patients in the U.S., and TONMYA offers a novel sublingual formulation designed for rapid absorption. The company's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra.
Beyond TONMYA, Tonix is advancing a robust pipeline. The company is conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder. Additionally, TNX-2900 is Phase 2 ready for Prader-Willi syndrome, a rare disease with no approved therapies. In immunology, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
The investor conferences provide a platform for Tonix to showcase its commercial-stage capabilities and pipeline progress. The company's focus on high unmet medical needs in CNS and immunology positions it as a key player in these therapeutic areas. With TONMYA now approved, Tonix is poised to generate revenue while advancing its later-stage candidates.
For investors, these presentations offer insights into the company's strategy and milestones. The full press release is available at https://ibn.fm/ZZpG2. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
